期刊文献+

临床试验中生物研究用药物质量文件要求指南

Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials
原文传递
导出
摘要 欧洲药品管理局(European Medicines Agency,EMA)于2010年发布了临床试验中生物研究用药物质量文件要求指南。参考该指南,本文主要就生物研究用药物在临床试验申请中的生物学、医学和药学质量文件要求的相关内容做了简要介绍,采用通用技术文件格式对各部分内容做了较为详细的阐述,并提出了明确的技术要求。 medicinal products mainly described th vestigational medici Guideline on the requirements for quality documentation concerning biological investigational in clinical trials was issued by European Medicines Agency (EMA) in 2010. In this paper, we e information on the biological, chemical and pharmaceutical quality concerning biological innal products in clinical trials. Researchers should use the common technical document format to do a detailed description for each part, and put forward a clear technical requirements
出处 《中国新药杂志》 CAS CSCD 北大核心 2012年第20期2408-2410,2440,共4页 Chinese Journal of New Drugs
基金 国家"重大新药创制"科技重大专项(2012ZX09303004)
关键词 生物制剂 研究用药物 临床试验 质量文件 质量要求 biological product investigational medicinal products clinical trial quality documentation quality requirement
  • 相关文献

参考文献5

  • 1ROTHWELL PM. Clinical trials are too often founded on poor quality pre-clinical research[J]. J Neurol, 2005, 252(9) . 1115.
  • 2EMEA. Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials [ EB/OL ]. (2010 - 02 - 18 ). http .//www. ema. europa. eu/ docs/ en_G B / document_library / Scientific_guideline/2010 /03 / WC500075559. pdf.
  • 3于红,马玉楠.FDA与EMA关于化学药申请Ⅰ期临床试验相关药学质量文件要求简介[J].中国临床药理学杂志,2011,27(6):476-480. 被引量:2
  • 4国家食品药品监督管理局.《药物临床试验质量管理规范》(局令第3号)[EB/OL].(2003-08-06).http.//www.sfda.gov.cn/WS01/CL0053/24473.html.
  • 5国家食品药品监督管理局.药物Ⅰ期临床试验管理指导原则(试行)[EB/OL].(2011-12-02).http.//www.sfda.gov.cn/WS01/CL0844/67396.html.

二级参考文献3

  • 1国家食品药品监督管理局.药品注册管理办法[EB/OL].2007-07-10[2009-01-12].http://www.sfda.gov.cn/WS01/CL0053/24529.html.
  • 2FDA.Guidance for Industry:Content and format of investigational new drug applications(INDs)for phase 1 studies of drugs,including well-characterized,therapeutic,biotechnology-derived products[EB/OL].http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm065008.htm.1995-11-16.
  • 3EMEA:Guideline on the requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials[EB/OL].http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003484.pdf,2006-03-31.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部